http://orcid.org/0000-0002-5527-4821
![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Objective. Dyslipidemia is commonly associated with endothelial dysfunction and increased cardiovascular risk. Pitavastatin has been shown to reduce total and low-density lipoprotein cholesterol, to increase high-density lipoprotein (HDL)-cholesterol and improve HDL function. Furthermore, several trials explored its effects on flow-mediated dilation (FMD), as an index of endothelial function. The authors evaluated the effect of pitavastatin therapy on FMD.
Methods. The authors performed a systematic review and meta-analysis of all clinical trials exploring the impact of pitavastatin on FMD. The search included PubMed-Medline, Scopus, ISI Web of Knowledge and Google Scholar databases. Quantitative data synthesis was performed using a random-effects model, with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics.
Results. Six eligible studies comprising 7 treatment arms were selected for this meta-analysis. Overall, WMD was significant for the effect of pitavastatin on FMD (2.45%, 95% CI: 1.31, 3.60, p < 0.001) and the effect size was robust in the leave-one-out sensitivity analysis.
Conclusion. This meta-analysis of all available clinical trials revealed a significant increase of FMD induced by pitavastatin.
Declaration of interest
N Katsiki has given talks, attended conferences and participated in trials sponsored by Amgen Inc, Angelini, AstraZeneca, Boehringer Ingelheim, Merck Sharp Doehme, Novartis, Novo Nordisk, Sanofi and WinMedica. K Al Rasadi received research grant from Sanofi, served on the speaker’s bureau and as an advisory board member for Sanofi, AstraZeneca and Pfizer Inc. DP Mikhailidis has given talks and attended conferences sponsored by Merck Sharp and Dohme, AstraZeneca and Libytec. The other authors declare no conflict of interest. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.